Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from February 2021.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from February 2021.
5. Cancer Drugs Spark Hope in Combatting COVID-19
In response to the COVID-19 pandemic, investigators around the world channeled their efforts into acquiring a better understanding of the virus so that they could rapidly identify any weapons that may be used in the fight against its spread; this included turning to tried-and-true cancer drugs to see whether they could be repurposed to address this pressing need.
4. Better Care for Minorities, Improved Telehealth: Next Steps in Lung Cancer
In light of the numerous advances that have led to improved outcomes for patients with lung cancer, the field should work to devote more research to minority populations who have been historically underrepresented in clinical trials, said Rogerio C. Lilenbaum, MD, who added that formal training on telehealth services is also needed to ensure these advances are accessible to every patient.
3. Telehealth: Hope or Hype?
The pandemic brought telehealth into the mainstream, but will it stay there after the COVID-19 pandemic is over, especially as the population ages? We explore the pros and cons of telemedicine in this piece.
2. Ruxolitinib Is Promising in Pediatric Chronic GVHD
Ruxolitinib (Jakafi), when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease (GVHD) with acceptable safety, according to preliminary findings presented during the 2021 Transplantation & Cellular Therapy Meeting.
1. Cancer Prevention: Why, Who, When, Where, How
While cancer continues to be a leading cause of death globally, oncology nursing is constantly evolving and expanding to meet emerging needs. Learn more in this piece about the role oncology nurses can play in cancer prevention.
Thanks for reading!
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.